Compare · BBNX vs BSX
BBNX vs BSX
Side-by-side comparison of Beta Bionics Inc. (BBNX) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBNX and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $62.32B, about 70.2x BBNX ($888.1M).
- Over the past year, BBNX is down 18.3% and BSX is down 54.9% - BBNX leads by 36.6 points.
- BBNX has been more active in the news (10 items in the past 4 weeks vs 5 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 21 for BBNX).
- Company
- Beta Bionics Inc.
- Boston Scientific Corporation
- Price
- $16.89-2.62%
- $44.06-0.22%
- Market cap
- $888.1M
- $62.32B
- 1M return
- -21.32%
- +1.26%
- 1Y return
- -18.31%
- -54.89%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 10
- 5
- Recent ratings
- 21
- 25
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BBNX
- BBNX DEADLINE: Levi & Korsinsky Reminds Beta Bionics, Inc. Investors of Upcoming Securities Class Action Deadline
- Jefferies initiated coverage on Beta Bionics with a new price target
- BBNX Investor Alert: Beta Bionics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
- SEC Form SCHEDULE 13G filed by Beta Bionics Inc.
- Barclays initiated coverage on Beta Bionics with a new price target
- SEC Form 4 filed by Beta Bionics Inc.
- Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026
- Director Jones Christy sold $147,890 worth of shares (6,430 units at $23.00) as part of a pre-agreed trading plan, decreasing direct ownership by 25% to 19,564 units (SEC Form 4)
- Wells Fargo initiated coverage on Beta Bionics with a new price target
- Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events